Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder. / Kaczmarek, Krystian; Plage, Henning; Furlano, Kira; Hofbauer, Sebastian; Weinberger, Sarah; Ralla, Bernhard; Franz, Antonia; Fendler, Annika; de Martino, Michela; Roßner, Florian; Schallenberg, Simon; Elezkurtaj, Sefer; Kluth, Martina; Lennartz, Maximilian; Blessin, Niclas C.; Marx, Andreas H.; Samtleben, Henrik; Fisch, Margit; Rink, Michael; Slojewski, Marcin; Ecke, Thorsten; Hallmann, Steffen; Koch, Stefan; Adamini, Nico; Minner, Sarah; Simon, Ronald; Sauter, Guido; Weischenfeldt, Joachim; Klatte, Tobias; Schlomm, Thorsten; Horst, David; Zecha, Henrik.
In: International Urology and Nephrology, Vol. 56, 2024, p. 499-508.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder
AU - Kaczmarek, Krystian
AU - Plage, Henning
AU - Furlano, Kira
AU - Hofbauer, Sebastian
AU - Weinberger, Sarah
AU - Ralla, Bernhard
AU - Franz, Antonia
AU - Fendler, Annika
AU - de Martino, Michela
AU - Roßner, Florian
AU - Schallenberg, Simon
AU - Elezkurtaj, Sefer
AU - Kluth, Martina
AU - Lennartz, Maximilian
AU - Blessin, Niclas C.
AU - Marx, Andreas H.
AU - Samtleben, Henrik
AU - Fisch, Margit
AU - Rink, Michael
AU - Slojewski, Marcin
AU - Ecke, Thorsten
AU - Hallmann, Steffen
AU - Koch, Stefan
AU - Adamini, Nico
AU - Minner, Sarah
AU - Simon, Ronald
AU - Sauter, Guido
AU - Weischenfeldt, Joachim
AU - Klatte, Tobias
AU - Schlomm, Thorsten
AU - Horst, David
AU - Zecha, Henrik
N1 - Publisher Copyright: © 2023, The Author(s).
PY - 2024
Y1 - 2024
N2 - Background: Uroplakin-1a (Upk1a) and uroplakin-1b (Upk1b) have recently been identified as diagnostic markers for the distinction of urothelial carcinomas from other solid tumor entities. Both proteins play an important role in the stabilization and strengthening of epithelial cells that line the bladder. Methods: To evaluate the prognostic role of uroplakin expression in urothelial carcinomas, more than 2700 urothelial neoplasms were analyzed in a tissue microarray format by immunohistochemistry. To further assess the diagnostic role of uroplakin immunohistochemistry, results were compared with preexisting GATA3 data. Result: The fraction of Upk1a/Upk1b positive cases decreased slightly from pTaG2 low-grade (88% positive for Upk1a/87% positive for Upk1b) and pTaG2 high-grade (92%/89%) to pTaG3 (83%/88%; p > 0.05) and was lower in muscle-invasive (pT2-4) carcinomas (42%/64%; p < 0.0001/p < 0.0001 for pTa vs. pT2-4). Within pT2-4 carcinomas, high expression of Upk1a and Upk1b was linked to nodal metastasis and lymphatic vessel infiltration (p < 0.05) but unrelated to patient outcome. There were significant associations between Upk1a, Upk1b and GATA3 immunostaining (p < 0.0001 each), but 11% of GATA3 negative cancers were Upk1a/b positive and 8% of Upk1a/b negative cancers were GATA3 positive. Absence of GATA3/Upk1a/b staining was significantly linked to poor patient survival in the subgroup of 126 pT4 carcinomas (p = 0.0004) but not in pT2 and pT3 cancers. Conclusions: In summary, the results of our study demonstrate that Upk1a and/or Upk1b immunohistochemistry can complement GATA3 for the distinction of urothelial carcinomas. Furthermore, a progressive loss of Upk1a/b expression during stage progression and a prognostic role of the combination GATA3/Upk1a/Upk1b in pT4 carcinomas is evident.
AB - Background: Uroplakin-1a (Upk1a) and uroplakin-1b (Upk1b) have recently been identified as diagnostic markers for the distinction of urothelial carcinomas from other solid tumor entities. Both proteins play an important role in the stabilization and strengthening of epithelial cells that line the bladder. Methods: To evaluate the prognostic role of uroplakin expression in urothelial carcinomas, more than 2700 urothelial neoplasms were analyzed in a tissue microarray format by immunohistochemistry. To further assess the diagnostic role of uroplakin immunohistochemistry, results were compared with preexisting GATA3 data. Result: The fraction of Upk1a/Upk1b positive cases decreased slightly from pTaG2 low-grade (88% positive for Upk1a/87% positive for Upk1b) and pTaG2 high-grade (92%/89%) to pTaG3 (83%/88%; p > 0.05) and was lower in muscle-invasive (pT2-4) carcinomas (42%/64%; p < 0.0001/p < 0.0001 for pTa vs. pT2-4). Within pT2-4 carcinomas, high expression of Upk1a and Upk1b was linked to nodal metastasis and lymphatic vessel infiltration (p < 0.05) but unrelated to patient outcome. There were significant associations between Upk1a, Upk1b and GATA3 immunostaining (p < 0.0001 each), but 11% of GATA3 negative cancers were Upk1a/b positive and 8% of Upk1a/b negative cancers were GATA3 positive. Absence of GATA3/Upk1a/b staining was significantly linked to poor patient survival in the subgroup of 126 pT4 carcinomas (p = 0.0004) but not in pT2 and pT3 cancers. Conclusions: In summary, the results of our study demonstrate that Upk1a and/or Upk1b immunohistochemistry can complement GATA3 for the distinction of urothelial carcinomas. Furthermore, a progressive loss of Upk1a/b expression during stage progression and a prognostic role of the combination GATA3/Upk1a/Upk1b in pT4 carcinomas is evident.
KW - Diagnostic marker
KW - Immunohistochemistry
KW - Tissue microarray
KW - Upk1a
KW - Upk1b
KW - Urothelial carcinoma
U2 - 10.1007/s11255-023-03800-0
DO - 10.1007/s11255-023-03800-0
M3 - Journal article
C2 - 37777995
AN - SCOPUS:85173044422
VL - 56
SP - 499
EP - 508
JO - International Urology and Nephrology
JF - International Urology and Nephrology
SN - 0301-1623
ER -
ID: 369924579